Evidence map›Paper›PMID 36875204›Full record

ArticleInfluenza and other respiratory viruses2023

Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort.

Sydney R Fine, Latifa A Bazzi, Amy P Callear, Joshua G Petrie, Ryan E Malosh, Joshua E Foster-Tucker, Matthew Smith, Jessica Ibiebele, Adrian McDermott, Melissa A Rolfes and 2 more

Open access · goldAbstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Respiratory virus circulation during pandemic: Why were some viruses still circulating?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Sydney R FineDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Latifa A BazziDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Amy P CallearDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Joshua G PetrieDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Ryan E MaloshDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.ORCID 0000-0003-3546-5935
Joshua E Foster-TuckerDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.ORCID 0000-0003-1548-1495
Matthew SmithDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Jessica IbiebeleDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Adrian McDermottVaccine Research Center National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda Maryland USA.
Melissa A RolfesInfluenza Division Centers for Disease Control and Prevention Atlanta Georgia USA.ORCID 0000-0002-0483-9941
Arnold S MontoDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.
Emily T MartinDepartment of Epidemiology University of Michigan Ann Arbor Michigan USA.ORCID 0000-0002-5771-8895
University of Michigan · USCenters for Disease Control and Prevention · USMichigan Department of Health and Human Services · USNational Institutes of Health · USNorthwestern University · US

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7M
US Influenza Vaccine Effectiveness NetworkU01IP001034 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2016 to 2020
$10.0M
ACL HHS U01IP001034NCIRD CDC HHS U01 IP001034NIAID NIH HHS 75N93021C00015
6 · The paper itself

Abstract

Background: The annual reappearance of respiratory viruses has been recognized for decades. COVID-19 mitigation measures taken during the pandemic were targeted at respiratory transmission and broadly impacted the burden of acute respiratory illnesses (ARIs). Methods: We used the longitudinal Household Influenza Vaccine Evaluation (HIVE) cohort in southeast Michigan to characterize the circulation of respiratory viruses from March 1, 2020, to June 30, 2021, using RT-PCR of respiratory specimens collected at illness onset. Participants were surveyed twice during the study period, and SARS-CoV-2 antibodies were measured in serum by electrochemiluminescence immunoassay. Incidence rates of ARI reports and virus detections were compared between the study period and a preceding pre-pandemic period of similar duration. Results: Overall, 437 participants reported a total of 772 ARIs; 42.6% had respiratory viruses detected. Rhinoviruses were the most frequent virus, but seasonal coronaviruses, excluding SARS-CoV-2, were also common. Illness reports and percent positivity were lowest from May to August 2020, when mitigation measures were most stringent. Seropositivity for SARS-CoV-2 was 5.3% in summer 2020 and increased to 11.3% in spring 2021. The incidence rate of total reported ARIs for the study period was 50% lower (95% CI: 0.5, 0.6; Conclusions: The burden of ARI in the HIVE cohort during the COVID-19 pandemic fluctuated, with declines occurring concurrently with the widespread use of public health measures. Rhinovirus and seasonal coronaviruses continued to circulate even when influenza and SARS-CoV-2 circulation was low.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesHumansPandemicsRhinovirusSARS-CoV-2Influenza VaccinesCOVID‐19household cohortinfluenzarespiratory virusserological surveillance

Identifiers

PMID36875204
PMCPMC9975790
OpenAlexW4323066817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.